Like the billions of public dollars for the private spa contract at Ontario Place, millions for the private jet, half-a-billion subsidizing corner store booze and so on, the Coalition is warning that ...
Depressive disorders and MND both affect a significant portion of people living with HIV in the United States and worldwide, even when their HIV is successfully managed and treated with antiretroviral ...
Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care - - Positions Humacyte to advance discussions with corporate partners regarding in ...
In celebration of DNA DAY™, A.D.A.M. Innovations Co. (Japanese corporate name Genesis Healthcare Co.) today announced a major update to GeneLife GeneAI Forecast, expanding the service to 15 AI-powered ...
Medicana Health Group has launched a new HPV vaccination and cervical cancer awareness campaign designed to expand prevention, strengthen public understanding, and reinforce trust in evidence-based ...
Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced the first patient has been dosed in a Japanese Phase 2 registrational clinical trial ...
TOKYO, April 24, 2026 (GLOBE NEWSWIRE) -- A.D.A.M. Innovations Co. (Japanese corporate name: Genesis Healthcare Co.) today announced GeneLock™, a new genomic security platform designed to help secure ...
A collaboration with Virginia Tech supports recognizing remission as a treatment outcome—capturing symptoms, quality of life, and functional outcomes—beyond abstinence alone Of all MOUD, monthly ...
Following completion of the Arrangement, Jushi expects the Nevada Common Stock will be listed for trading on the Canadian Securities Exchange and quoted on the OTCQX in place of the Subordinate Voting ...
Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that ...
Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today provided a corporate update on its ...
About GT-02287 Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results